Dermira, Inc. (DERM): Thomas G Wiggans , CEO & Chairman of the Board of Dermira, Inc. sold 11,000 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $31.34 per share for a total value of $347,261.09 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Eugene A Bauer (Chief Medical Officer) sold 2,500 shares at $31.65 per share price.On May 3, 2016, Thomas G Wiggans (CEO & Chairman of the Board) sold 9,000 shares at $25.11 per share price.
Shares of Dermira Inc (DERM) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.33 points or -1.08% at $30.33 with 6,34,648 shares getting traded. Post opening the session at $30.63, the shares hit an intraday low of $29.7 and an intraday high of $30.88 and the price vacillated in this range throughout the day. The company has a market cap of $910 M and the number of outstanding shares has been calculated to be 3,00,18,641 shares. The 52-week high of Dermira Inc is $35.75 and the 52-week low is $15.5.
Company has been under the radar of several Street Analysts.Dermira Inc is Reiterated by Wedbush to Outperform and the brokerage firm has raised the Price Target to $ 46 from a previous price target of $42 .The Rating was issued on Jun 2, 2016.Dermira Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 46 from a previous price target of $42 .The Rating was issued on Jun 2, 2016.Dermira Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 42 from a previous price target of $38 .The Rating was issued on May 11, 2016.
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.